64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
NCT04868604
This study is recruiting at 7 US sites in 7 states, according to its ClinicalTrials.gov record last updated .
Summary
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Prostatic Neoplasms, Castration-Resistant
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1/2
- Ages
- 18 years and older
- Sex
- Male
- Healthy volunteers
- Not accepted
- Sponsor
- Clarity Pharmaceuticals Ltd
- Last updated on ClinicalTrials.gov
- May 6, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Stanford Cancer Institute · Stanford, CA
Louisiana · 1
- East Jefferson General Hospital · River Ridge, LA
Michigan · 1
- BAMF Health · Grand Rapids, MI
Minnesota · 1
- Mayo Clinic · Rochester, MN
Missouri · 1
- Washington University School of Medicine at Barnes-Jewish Hospital · St Louis, MO
Nebraska · 1
- XCancer · Omaha, NE
New York · 1
- Weill Cornell Medicine at New York-Presbyterian · New York, NY
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.